Role of daratumumab in relapsed or refractory multiple myeloma patient: A meta-analysis and literature to review
Introduction: With an increase in number of cases of relapsed or refractory multiple myeloma (RRMM), scientist have discovered various combination of medications among which one is daratumumab, Daratumumab is a mono-clonal antibody which attacks CD-38 markers present in abundance on the surface of m...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2022-01-01
|
| Series: | Journal of Family Medicine and Primary Care |
| Subjects: | |
| Online Access: | http://www.jfmpc.com/article.asp?issn=2249-4863;year=2022;volume=11;issue=6;spage=2648;epage=2655;aulast=Tauseef |
| _version_ | 1811217620292075520 |
|---|---|
| author | Abubakar Tauseef Maryam Zafar Peter Silberstein Joseph Nahas Thomas Frederickson Faith Abodunrin Anum Abbas Wafa Arshad Noman Lateef Hussain Rangoonwala Sara Albagoush Mohsin Mirza |
| author_facet | Abubakar Tauseef Maryam Zafar Peter Silberstein Joseph Nahas Thomas Frederickson Faith Abodunrin Anum Abbas Wafa Arshad Noman Lateef Hussain Rangoonwala Sara Albagoush Mohsin Mirza |
| author_sort | Abubakar Tauseef |
| collection | DOAJ |
| description | Introduction: With an increase in number of cases of relapsed or refractory multiple myeloma (RRMM), scientist have discovered various combination of medications among which one is daratumumab, Daratumumab is a mono-clonal antibody which attacks CD-38 markers present in abundance on the surface of myeloma cells and is used universally for the treatment of primary newly diagnosed multiple myeloma patients. Methods and Methodology: This meta-analysis was conducted according to Cochrane Collaboration guidelines in which initially 679 articles were evaluated for relevance on abstract level followed by full text screening of final list of 45 articles. Out of the 45 articles, only 10 articles qualified for selection criteria for eligibility. Three Phase 3 randomized control clinical trials which includes primary outcomes of progression free span and secondary outcomes including complete response, partial response or very good partial response and adverse effects reported were included in this study. Results: A total of three studies including 1533 patients (849 in Daratumumab treatment group while 684 patients in control group) were included in the study. All three of these studies were phase 3 clinical trial conducted to observe the role of daratumumab in relapsed and refractory multiple myeloma. Mean age reported was 65 years in both treatment and control groups. This study showed that daratumumab improves primary and secondary outcomes including progression free span, overall response rate, very good partial response, and complete response. However, daratumumab increases drug induced adverse effects. Conclusion: Our study confirmed that daratumumab in combination therapy improved primary and secondary outcomes when compared with platinum-based chemotherapy, but more adverse effects were reported in the combination group. So, we recommend that combination therapy should include daratumumab in treatment of relapsed and refractory multiple myeloma patients. |
| first_indexed | 2024-04-12T06:57:49Z |
| format | Article |
| id | doaj.art-13589fc04d3747cf9849f8471bea1a71 |
| institution | Directory Open Access Journal |
| issn | 2249-4863 |
| language | English |
| last_indexed | 2024-04-12T06:57:49Z |
| publishDate | 2022-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Journal of Family Medicine and Primary Care |
| spelling | doaj.art-13589fc04d3747cf9849f8471bea1a712022-12-22T03:43:06ZengWolters Kluwer Medknow PublicationsJournal of Family Medicine and Primary Care2249-48632022-01-011162648265510.4103/jfmpc.jfmpc_1987_21Role of daratumumab in relapsed or refractory multiple myeloma patient: A meta-analysis and literature to reviewAbubakar TauseefMaryam ZafarPeter SilbersteinJoseph NahasThomas FredericksonFaith AbodunrinAnum AbbasWafa ArshadNoman LateefHussain RangoonwalaSara AlbagoushMohsin MirzaIntroduction: With an increase in number of cases of relapsed or refractory multiple myeloma (RRMM), scientist have discovered various combination of medications among which one is daratumumab, Daratumumab is a mono-clonal antibody which attacks CD-38 markers present in abundance on the surface of myeloma cells and is used universally for the treatment of primary newly diagnosed multiple myeloma patients. Methods and Methodology: This meta-analysis was conducted according to Cochrane Collaboration guidelines in which initially 679 articles were evaluated for relevance on abstract level followed by full text screening of final list of 45 articles. Out of the 45 articles, only 10 articles qualified for selection criteria for eligibility. Three Phase 3 randomized control clinical trials which includes primary outcomes of progression free span and secondary outcomes including complete response, partial response or very good partial response and adverse effects reported were included in this study. Results: A total of three studies including 1533 patients (849 in Daratumumab treatment group while 684 patients in control group) were included in the study. All three of these studies were phase 3 clinical trial conducted to observe the role of daratumumab in relapsed and refractory multiple myeloma. Mean age reported was 65 years in both treatment and control groups. This study showed that daratumumab improves primary and secondary outcomes including progression free span, overall response rate, very good partial response, and complete response. However, daratumumab increases drug induced adverse effects. Conclusion: Our study confirmed that daratumumab in combination therapy improved primary and secondary outcomes when compared with platinum-based chemotherapy, but more adverse effects were reported in the combination group. So, we recommend that combination therapy should include daratumumab in treatment of relapsed and refractory multiple myeloma patients.http://www.jfmpc.com/article.asp?issn=2249-4863;year=2022;volume=11;issue=6;spage=2648;epage=2655;aulast=Tauseefdaratumumabliteraturemultiple myelomarefractoryrelapsedrole |
| spellingShingle | Abubakar Tauseef Maryam Zafar Peter Silberstein Joseph Nahas Thomas Frederickson Faith Abodunrin Anum Abbas Wafa Arshad Noman Lateef Hussain Rangoonwala Sara Albagoush Mohsin Mirza Role of daratumumab in relapsed or refractory multiple myeloma patient: A meta-analysis and literature to review Journal of Family Medicine and Primary Care daratumumab literature multiple myeloma refractory relapsed role |
| title | Role of daratumumab in relapsed or refractory multiple myeloma patient: A meta-analysis and literature to review |
| title_full | Role of daratumumab in relapsed or refractory multiple myeloma patient: A meta-analysis and literature to review |
| title_fullStr | Role of daratumumab in relapsed or refractory multiple myeloma patient: A meta-analysis and literature to review |
| title_full_unstemmed | Role of daratumumab in relapsed or refractory multiple myeloma patient: A meta-analysis and literature to review |
| title_short | Role of daratumumab in relapsed or refractory multiple myeloma patient: A meta-analysis and literature to review |
| title_sort | role of daratumumab in relapsed or refractory multiple myeloma patient a meta analysis and literature to review |
| topic | daratumumab literature multiple myeloma refractory relapsed role |
| url | http://www.jfmpc.com/article.asp?issn=2249-4863;year=2022;volume=11;issue=6;spage=2648;epage=2655;aulast=Tauseef |
| work_keys_str_mv | AT abubakartauseef roleofdaratumumabinrelapsedorrefractorymultiplemyelomapatientametaanalysisandliteraturetoreview AT maryamzafar roleofdaratumumabinrelapsedorrefractorymultiplemyelomapatientametaanalysisandliteraturetoreview AT petersilberstein roleofdaratumumabinrelapsedorrefractorymultiplemyelomapatientametaanalysisandliteraturetoreview AT josephnahas roleofdaratumumabinrelapsedorrefractorymultiplemyelomapatientametaanalysisandliteraturetoreview AT thomasfrederickson roleofdaratumumabinrelapsedorrefractorymultiplemyelomapatientametaanalysisandliteraturetoreview AT faithabodunrin roleofdaratumumabinrelapsedorrefractorymultiplemyelomapatientametaanalysisandliteraturetoreview AT anumabbas roleofdaratumumabinrelapsedorrefractorymultiplemyelomapatientametaanalysisandliteraturetoreview AT wafaarshad roleofdaratumumabinrelapsedorrefractorymultiplemyelomapatientametaanalysisandliteraturetoreview AT nomanlateef roleofdaratumumabinrelapsedorrefractorymultiplemyelomapatientametaanalysisandliteraturetoreview AT hussainrangoonwala roleofdaratumumabinrelapsedorrefractorymultiplemyelomapatientametaanalysisandliteraturetoreview AT saraalbagoush roleofdaratumumabinrelapsedorrefractorymultiplemyelomapatientametaanalysisandliteraturetoreview AT mohsinmirza roleofdaratumumabinrelapsedorrefractorymultiplemyelomapatientametaanalysisandliteraturetoreview |